Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.

Proteomics. Clinical applications - 1 Jul 2016

Rovithi Maria, Lind Joline S W, Pham Thang V, Voortman Johannes, Knol Jaco C, Verheul Henk M W, Smit Egbert F, Jimenez Connie R

Abstract excerpt

PURPOSE: We validated a previously reported proteomic signature, associated with treatment outcome, in an independent cohort of patients with non-small cell lung cancer (NSCLC). A novel peptide signature was developed to predict toxicity. EXPERIMENTAL DESIGN: Using automated magnetic C18 bead-assisted serum peptide capture coupled to MALDI-TOF MS, we conducted serum peptide profiling of 50 NCSLC patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Niacinamide

Share to Phenylurea Compounds

Share to Proteomics

Share to Sorafenib

Share to Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Source

Identifiers

PMID: 27040893
DOI: 10.1002/prca.201600025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.PMID 27040893Read ↗

Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancerSemantic proximity Read ↗

Screening anlotinib responders via blood-based proteomics in non-small cell lung cancerSemantic proximity Read ↗

Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study.Semantic proximity Read ↗

Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)Semantic proximity Read ↗

Bioinformatics analysis of NSCLC multi-omics dataSemantic proximity Read ↗

Extracellular vesicles proteomics-based machine-learning model predicts immunotherapy response in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.